Introduction: Despite advances in screening and treatment options, colorectal cancer (CRC) remains one of the most prevalent and lethal cancer subtypes. Resistance to cytotoxic or targeted therapy has remained a constant challenge to the treatment and long-term management of patients, attracting intense worldwide investigation since the 1950s. Through extensive investigations into the proteomic mechanisms and functions that convey resistance to therapy/s, researchers have become able to implicate alterations in several signaling pathways that provide and sustain resistance to treatment.Areas covered: In this review, we summarize how protein alterations are associated with resistance to therapy, with particular emphasis on CRC. An overview of the mechanisms of therapeutic resistance is described, highlighting recent studies which endeavor to elucidate the proteomic changes that are associated with the acquisition and promulgation of therapeutic resistance.Expert opinion: While cancers such as CRC have been intensively studied for decades, unresponsiveness and the resistance to therapy remain critical obstacles in the treatment of patients. Due to the inherent biological and clinical heterogeneity of individual CRCs, proteomic methods stand to become powerful tools to provide biological insights that may guide therapeutic strategies with the ultimate goal of refining emergent immunotherapeutic treatments.

中文翻译：

---

结直肠癌耐药性的蛋白质组学研究。

简介：尽管筛查和治疗方案取得了进步，但结直肠癌 (CRC) 仍然是最普遍和最致命的癌症亚型之一。自 1950 年代以来，对细胞毒性或靶向治疗的耐药性一直是患者治疗和长期管理的持续挑战，吸引了全球范围内的广泛调查。通过对表达治疗耐药性的蛋白质组学机制和功能的广泛研究，研究人员已经能够暗示提供和维持治疗耐药性的几个信号通路的改变。 涵盖的领域：在这篇评论中，我们总结了蛋白质改变是如何关联的对治疗有抵抗力，特别强调 CRC。描述了治疗抵抗机制的概述，强调最近的研究，这些研究致力于阐明与治疗耐药性的获得和传播相关的蛋白质组学变化。 专家意见：虽然 CRC 等癌症已被深入研究了几十年，但无反应性和对治疗的耐药性仍然是治疗耐药性的关键障碍耐心。由于个体 CRC 固有的生物学和临床异质性，蛋白质组学方法将成为提供生物学见解的强大工具，可以指导治疗策略，最终目标是完善紧急免疫治疗。反应迟钝和对治疗的抵抗仍然是患者治疗中的关键障碍。由于个体 CRC 固有的生物学和临床异质性，蛋白质组学方法将成为提供生物学见解的强大工具，可以指导治疗策略，最终目标是完善紧急免疫治疗。反应迟钝和对治疗的抵抗仍然是患者治疗中的关键障碍。由于个体 CRC 固有的生物学和临床异质性，蛋白质组学方法将成为提供生物学见解的强大工具，可以指导治疗策略，最终目标是完善紧急免疫治疗。